Wall Street is in the heart of earnings season with three key biotechnology stocks slated to announce their quarterly financial results this week. …
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) and Paladin Labs Inc.
Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) announced updated clinical data on its investigational tyrosine kinase inhibitor (TKI), brigatinib (AP26113), in patients with anaplastic lymphoma kinase …
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) reported financial results for the first quarter of 2015, including revenue from sales of Iclusig® (ponatinib).
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that it has reached an agreement to settle its current proxy contest with Sarissa Capital Management.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced that its founder, Harvey J.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced the issuance of its first U.
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced the results of a series of preclinical studies on its investigational tyrosine kinase inhibitor (TKI), brigatinib (AP26113) at …
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) announced updated clinical data on its investigational tyrosine kinase inhibitor, brigatinib (AP26113),in patients with anaplastic lymphoma kinase positive (ALK+) …
ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA), today announced that Health Canada has approved the use of Iclusig™ (as ponatinib hydrochloride) in Canada for the treatment of adult patients with all …
